| Code | Description | Claims | Beneficiaries | Total Paid |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
13,599 |
10,396 |
$832K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,973 |
8,477 |
$638K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
8,332 |
6,383 |
$599K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,704 |
4,391 |
$497K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,042 |
4,862 |
$471K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,445 |
1,309 |
$386K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,379 |
878 |
$374K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
3,987 |
1,278 |
$294K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,216 |
2,830 |
$268K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,848 |
3,372 |
$167K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
886 |
823 |
$152K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
590 |
442 |
$137K |
| 70450 |
Computed tomography, head or brain; without contrast material |
563 |
444 |
$111K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,481 |
591 |
$98K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,369 |
1,234 |
$95K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,015 |
638 |
$81K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,148 |
2,722 |
$68K |
| 80053 |
Comprehensive metabolic panel |
2,566 |
2,135 |
$62K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,859 |
508 |
$60K |
| G0378 |
Hospital observation service, per hour |
929 |
367 |
$60K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
241 |
191 |
$56K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
9,164 |
6,999 |
$54K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
518 |
461 |
$51K |
| 97803 |
|
593 |
560 |
$49K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
773 |
729 |
$42K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
292 |
150 |
$42K |
| 71046 |
Radiologic examination, chest; 2 views |
1,451 |
1,213 |
$34K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,158 |
1,795 |
$34K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,861 |
8,412 |
$31K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
262 |
229 |
$25K |
| 84439 |
|
993 |
850 |
$23K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,144 |
903 |
$22K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
565 |
475 |
$21K |
| 87632 |
|
184 |
141 |
$21K |
| 36415 |
Collection of venous blood by venipuncture |
16,161 |
11,778 |
$21K |
| 97161 |
|
562 |
482 |
$20K |
| 80061 |
Lipid panel |
1,418 |
1,233 |
$20K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
248 |
103 |
$20K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
125 |
89 |
$16K |
| 87070 |
|
939 |
734 |
$12K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
916 |
807 |
$12K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,005 |
834 |
$11K |
| J3490 |
Unclassified drugs |
1,088 |
398 |
$11K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
2,515 |
2,134 |
$11K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
561 |
471 |
$10K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,955 |
1,627 |
$10K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
712 |
672 |
$10K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
420 |
368 |
$10K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,106 |
2,392 |
$10K |
| 87081 |
|
505 |
433 |
$9K |
| 80076 |
|
3,712 |
2,995 |
$9K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
83 |
65 |
$8K |
| 86140 |
|
637 |
491 |
$8K |
| 74018 |
|
150 |
109 |
$7K |
| 87088 |
|
1,108 |
765 |
$7K |
| 82728 |
|
353 |
290 |
$6K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
1,075 |
871 |
$6K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
113 |
40 |
$5K |
| 82607 |
|
237 |
216 |
$5K |
| 87077 |
|
763 |
562 |
$5K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
257 |
215 |
$5K |
| 81001 |
|
3,760 |
3,037 |
$5K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
16 |
13 |
$4K |
| 82570 |
|
362 |
313 |
$3K |
| 87205 |
|
737 |
552 |
$3K |
| 87186 |
|
745 |
556 |
$3K |
| 83735 |
|
1,385 |
933 |
$3K |
| 99215 |
Prolong outpt/office vis |
46 |
38 |
$3K |
| 83540 |
|
299 |
244 |
$3K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
244 |
212 |
$3K |
| A0425 |
Ground mileage, per statute mile |
50 |
36 |
$3K |
| 84484 |
|
2,169 |
1,366 |
$3K |
| 86850 |
|
102 |
77 |
$3K |
| 83550 |
|
282 |
228 |
$3K |
| 99233 |
Prolong inpt eval add15 m |
188 |
100 |
$3K |
| 86592 |
|
130 |
108 |
$2K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
229 |
147 |
$2K |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
106 |
88 |
$2K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
39 |
31 |
$2K |
| 85651 |
|
448 |
385 |
$2K |
| 0012A |
|
67 |
54 |
$2K |
| 82947 |
|
1,143 |
431 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
1,032 |
847 |
$2K |
| 83690 |
|
1,263 |
940 |
$2K |
| Q3014 |
Telehealth originating site facility fee |
90 |
85 |
$2K |
| 81003 |
|
450 |
372 |
$2K |
| 83880 |
|
383 |
326 |
$2K |
| 0011A |
|
75 |
54 |
$2K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
348 |
226 |
$2K |
| 85610 |
|
560 |
446 |
$1K |
| 86900 |
|
128 |
103 |
$1K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,225 |
776 |
$1K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
321 |
259 |
$1K |
| 87340 |
|
76 |
59 |
$1K |
| 82043 |
|
174 |
162 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,143 |
760 |
$1K |
| 73630 |
|
46 |
45 |
$940.29 |
| 85027 |
|
360 |
250 |
$887.20 |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
166 |
106 |
$881.98 |
| 87210 |
|
76 |
57 |
$808.24 |
| 86901 |
|
128 |
103 |
$748.58 |
| 86803 |
|
34 |
27 |
$620.23 |
| 81025 |
|
837 |
570 |
$599.50 |
| 99238 |
Hospital discharge day management, 30 minutes or less |
51 |
43 |
$577.18 |
| 82746 |
|
49 |
41 |
$538.43 |
| 85007 |
|
152 |
95 |
$506.77 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,296 |
981 |
$479.58 |
| 84403 |
|
17 |
12 |
$476.61 |
| 86038 |
|
18 |
12 |
$430.16 |
| 84702 |
|
19 |
13 |
$415.35 |
| 84145 |
|
43 |
28 |
$408.69 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
945 |
718 |
$387.00 |
| 82077 |
|
512 |
350 |
$384.97 |
| 99223 |
Prolong inpt eval add15 m |
13 |
13 |
$346.29 |
| 73130 |
|
22 |
14 |
$334.95 |
| 73610 |
|
21 |
12 |
$333.87 |
| 83605 |
|
299 |
187 |
$284.15 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
779 |
448 |
$248.76 |
| 11721 |
|
13 |
13 |
$247.79 |
| 97116 |
|
27 |
16 |
$244.73 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,179 |
804 |
$225.82 |
| 73030 |
|
19 |
12 |
$223.63 |
| 82950 |
|
19 |
14 |
$206.19 |
| 86308 |
|
21 |
13 |
$203.90 |
| 73560 |
|
34 |
25 |
$171.57 |
| 99239 |
Hospital discharge day management, more than 30 minutes |
18 |
15 |
$169.21 |
| 85379 |
|
111 |
81 |
$154.48 |
| 87040 |
|
340 |
160 |
$149.88 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
549 |
263 |
$126.86 |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
19 |
13 |
$114.13 |
| 85730 |
|
128 |
106 |
$94.08 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,108 |
714 |
$84.04 |
| 84100 |
|
25 |
12 |
$75.36 |
| 80179 |
|
150 |
108 |
$74.59 |
| J2704 |
Injection, propofol, 10 mg |
951 |
564 |
$53.90 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
510 |
337 |
$39.56 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,378 |
886 |
$30.14 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
785 |
482 |
$30.04 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
419 |
341 |
$29.21 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
351 |
211 |
$22.17 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
143 |
94 |
$13.46 |
| 80143 |
|
145 |
107 |
$11.38 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
57 |
41 |
$6.09 |
| J7050 |
Infusion, normal saline solution, 250 cc |
102 |
68 |
$3.93 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
39 |
38 |
$3.89 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
48 |
30 |
$0.72 |
| 91301 |
|
93 |
88 |
$0.69 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
20 |
17 |
$0.10 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
93 |
52 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
23 |
13 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
26 |
14 |
$0.00 |
| 29515 |
|
12 |
12 |
$0.00 |
| 96376 |
|
122 |
80 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
13 |
13 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
19 |
12 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
12 |
12 |
$0.00 |
| 76830 |
Ultrasound, transvaginal |
16 |
13 |
$0.00 |